HONG KONG: Capital Group Cos, the US asset manager that has been backing startups in emerging markets, is in talks to invest in Chinese biopharmaceutical firm Innovent Biologics Inc, people with knowledge of the matter said.
Capital Group would join other investors in a funding round for Innovent ahead of a planned listing, according to the people.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
